BCMA2TGFbetaNeg

N/A

Report date: 2025/01/26 18:26:26

Base Information

Drug NameBCMA2TGFbetaNeg

Drug Alias Nameanti-BCMA CAR T-cell therapy (Lentigen)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionTumor necrosis factor ligand superfamily member 13 modulators

TargetsTumor necrosis factor ligand superfamily member 13

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesLentigen Technology Inc

China Registration ClassN/A

Develop Information

Active CompaniesLentigen Technology Inc

Inactive CompaniesN/A

Active IndicationsMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A